Literature DB >> 19727145

Prostate cancer: PSA as an intermediate end point in clinical trials.

Gerhardt Attard, Johann S de Bono.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19727145     DOI： 10.1038/nrurol.2009.130

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

Authors:  Daniel P Petrylak; Donna Pauler Ankerst; Caroline S Jiang; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

2.  Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.

Authors:  Laurence Collette; Tomasz Burzykowski; Kevin J Carroll; Don Newling; Tom Morris; Fritz H Schröder
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

3.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Authors:  G J Bubley; M Carducci; W Dahut; N Dawson; D Daliani; M Eisenberger; W D Figg; B Freidlin; S Halabi; G Hudes; M Hussain; R Kaplan; C Myers; W Oh; D P Petrylak; E Reed; B Roth; O Sartor; H Scher; J Simons; V Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

4.  Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.

Authors:  Andrew J Armstrong; Elizabeth Garrett-Mayer; Yi-Chun Ou Yang; Michael A Carducci; Ian Tannock; Ronald de Wit; Mario Eisenberger
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

5.  Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

Authors:  Susan Halabi; Nicholas J Vogelzang; San-San Ou; Kouros Owzar; Laura Archer; Eric J Small
Journal:  J Clin Oncol       Date:  2009-04-20       Impact factor: 44.544

6.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.

Authors:  Maha Hussain; Bryan Goldman; Cathy Tangen; Celestia S Higano; Daniel P Petrylak; George Wilding; Atif M Akdas; Eric J Small; Bryan J Donnelly; Subramanian Kanaga Sundram; Patrick A Burch; Robert S Dipaola; E David Crawford
Journal:  J Clin Oncol       Date:  2009-04-20       Impact factor: 44.544

7.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

8.  Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Authors:  Gerhardt Attard; Joost F Swennenhuis; David Olmos; Alison H M Reid; Elaine Vickers; Roger A'Hern; Rianne Levink; Frank Coumans; Joana Moreira; Ruth Riisnaes; Nikhil Babu Oommen; George Hawche; Charles Jameson; Emilda Thompson; Ronald Sipkema; Craig P Carden; Christopher Parker; David Dearnaley; Stan B Kaye; Colin S Cooper; Arturo Molina; Michael E Cox; Leon W M M Terstappen; Johann S de Bono
Journal:  Cancer Res       Date:  2009-04-01       Impact factor: 12.701

9.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

10.  Speeding up the evaluation of new agents in cancer.

Authors:  Mahesh K B Parmar; Friederike M-S Barthel; Matthew Sydes; Ruth Langley; Rick Kaplan; Elizabeth Eisenhauer; Mark Brady; Nicholas James; Michael A Bookman; Ann-Marie Swart; Wendi Qian; Patrick Royston
Journal:  J Natl Cancer Inst       Date:  2008-08-26       Impact factor: 13.506
  10 in total
  6 in total

Review 1.  The changing therapeutic landscape of castration-resistant prostate cancer.

Authors:  Timothy A Yap; Andrea Zivi; Aurelius Omlin; Johann S de Bono
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

2.  Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.

Authors:  Alessandro Ruggiero; Jason P Holland; Tvrtko Hudolin; Larissa Shenker; Anna Koulova; Neil H Bander; Jason S Lewis; Jan Grimm
Journal:  J Nucl Med       Date:  2011-09-09       Impact factor: 10.057

3.  Translating cancer research into targeted therapeutics.

Authors:  J S de Bono; Alan Ashworth
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

4.  Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer.

Authors:  Christopher Weier; Michael C Haffner; Timothy Mosbruger; David M Esopi; Jessica Hicks; Qizhi Zheng; Helen Fedor; William B Isaacs; Angelo M De Marzo; William G Nelson; Srinivasan Yegnasubramanian
Journal:  J Pathol       Date:  2013-06       Impact factor: 7.996

Review 5.  Drug discovery in advanced prostate cancer: translating biology into therapy.

Authors:  Timothy A Yap; Alan D Smith; Roberta Ferraldeschi; Bissan Al-Lazikani; Paul Workman; Johann S de Bono
Journal:  Nat Rev Drug Discov       Date:  2016-07-22       Impact factor: 84.694

6.  Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studies.

Authors:  F Huber; M Montani; T Sulser; R Jaggi; P Wild; H Moch; H Gevensleben; M Schmid; S Wyder; G Kristiansen
Journal:  Br J Cancer       Date:  2014-11-25       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.